Bausch Health Responds to Market Rumors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Jefferies on Bausch Health Companies (BHC): 'Another Case of Irresponsible Journalism Wreaks Havoc in Shares'
July 24, 2024 3:43 PM EDTJefferies analyst Glen Santangelo reiterated a Buy rating and $13.00 price target on Bausch Health Companies (NYSE: BHC)
The analyst comments "This morning, a report from Reorg comments that BHC was negotiating a pre-packaged Chap 11 bankruptcy filing. BHC has since commented this is NOT true. This reminds us of the April Wall St Journal article that insinuated that one of Zoetiss drugs (Librela) was killing dogs! Both situations were unfounded. Unfortunately,... More
